This week, researchers presented findings in how ancestry affects cancer treatment, nanotechnology and genetic diseases. Here’s a look at that and more.
Neuronal Inflammation was found in two U.S. monkeypox patients, researchers short-list four drugs for potential study in autism and a new test can predict immunotherapy outcomes.
Researchers have discovered a potential treatment target for Down syndrome, Th17 cells could mitigate microbiome-linked diseases and electroacupuncture in Parkinson’s disease.
Pfizer’s RSV vaccine has produced promising data with an efficacy of 85.7% in adults over 60 with a more severe form of the disease. Data in hand, Pfizer plans to head to the FDA this Fall.
Researchers found promising connections between the Neuregulin 4 (NRG4) endocrine factor protein and the suppression of specific liver diseases, including NASH.
In a recently published study, researchers found that the link between the SOD1 protein and Amyotrophic Lateral Sclerosis (ALS) could extend to all types of the motor neuron disease.
